• KOL
    • Racemic Albuterol
    • David S Reasner
    • David S Reasner: Influence Statistics

      David S Reasner

      David S Reasner

      Chester, Pa, Portland, Ore, and Marlborough, Mass | From aAsthma and Allergy Research Associates, Chester; bAllergy Associates, PC, Portland; and cSepracor Inc, Marlborough | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      David S Reasner:Expert Impact

      Concepts for whichDavid S Reasnerhas direct influence:Racemic albuterol,Levalbuterol racemic albuterol,Nebulized levalbuterol,Levalbuterol placebo,Racemic albuterol placebo,Patients levalbuterol,Treatment levalbuterol,Racemic albuterol patients.

      David S Reasner:KOL impact

      Concepts related to the work of other authors for whichfor which David S Reasner has influence:Racemic albuterol,Acute asthma,Bronchodilator agents,Rac lev,Beta agonists,Allergic rhinitis.

      KOL Resume for David S Reasner

      Year
      1999

      Chester, Pa, Portland, Ore, and Marlborough, Mass

      From aAsthma and Allergy Research Associates, Chester; bAllergy Associates, PC, Portland; and cSepracor Inc, Marlborough

      1998

      Denver, Colo, Stockton and Encinitas, Calif, Wilmington, NC, and Marlborough, Mass

      Sign-in to see all concepts, it's free!
      Sample of concepts for which David S Reasner is among the top experts in the world.
      Concept World rank
      conclusion levalbuterol #2
      placebo fev1 values #2
      polgars values #2
      levalbuterol greater #2
      levalbuterol plasma levels #2
      efficacy nebulized levalbuterol #2
      nebulized beta2 agonists #2
      limited doseresponse #2
      levalbuterol plasma #2
      xopenex #3
      4 treatment visits #3
      levalbuterol 031 #3
      treatment levalbuterol #4
      125 racemic #4
      063 racemic #4
      levalbuterol patients #5
      racemic albuterol placebo #5
      combined racemic #6
      levalbuterol 063 #7
      levalbuterol compared #7
      racemic albuterol patients #8
      albuterol racemic #8
      doses levalbuterol #8
      racemic albuterol treatment #8
      received levalbuterol #9
      levalbuterol 125 #9
      levalbuterol placebo #11
      albuterol 125 #12
      25 racemic #14
      dose levalbuterol #15
      levels albuterol #15
      levalbuterol administered #17
      received racemic #18
      patients levalbuterol #19
      nebulized levalbuterol #20
      albuterol beta #24
      levalbuterol racemic albuterol #26
      albuterol levels #30
      levalbuterol albuterol #31
      albuterol 25 #33
      levalbuterol racemic #37
      asthma pediatric patients #40
      031 063 #43
      albuterol compared #51
      enantiomer levels #51
      levalbuterol #63
      compared racemic #68
      doses nebulized #70
      063 125 #72
      racemic albuterol #91
      Sign-in to see all concepts, it's free!

      Prominent publications by David S Reasner

      KOL-Index: 15015

      BACKGROUND: Limited dose-response information is available for nebulized beta2 -agonists, especially in young children.

      OBJECTIVE: The purpose of this study was to determine the safety and efficacy of increasing doses of nebulized levalbuterol (Xopenex; the pure R-isomer of racemic albuterol) and racemic albuterol compared with placebo in the treatment of asthma in pediatric patients.

      METHODS: In this randomized, double-blind, crossover study, children (aged 3 to 11 years) with asthma ...

      Known for Nebulized Levalbuterol | Pediatric Patients | Racemic Albuterol | Treatment Asthma | Placebo Fev1
      KOL-Index: 11357

      BACKGROUND: Racemic albuterol is an equal mixture of (R)-albuterol (levalbuterol), which is responsible for the bronchodilator effect, and (S)-albuterol, which provides no benefit and may be detrimental.

      OBJECTIVE: We sought to compare 2 doses of a single enantiomer, levalbuterol (0.63 mg and 1.25 mg), and equivalent amounts of levalbuterol administered as racemic albuterol with placebo in patients with moderate-to-severe asthma.

      METHODS: This was a randomized, double-blind, ...

      Known for Racemic Albuterol | Placebo Patients | 4 Weeks | Asthma Bronchodilator | Primary Endpoint

      Key People For Racemic Albuterol

      Top KOLs in the world
      #1
      Sidney S DeGraw
      racemic albuterol pediatric patients placebo treatment
      #2
      George W Bensch
      pulmicort turbuhaler mometasone furoate racemic albuterol
      #3
      David S Reasner
      racemic albuterol pediatric patients placebo treatment
      #4
      Harold S Nelson
      allergic rhinitis sublingual immunotherapy inhaled corticosteroids
      #5
      Warren W Pleskow
      racemic albuterol fluticasone propionate seasonal allergic rhinitis
      #6
      Thomas E Rollins
      racemic albuterol improved bronchodilation patients asthma

      Chester, Pa, Portland, Ore, and Marlborough, Mass | From aAsthma and Allergy Research Associates, Chester; bAllergy Associates, PC, Portland; and cSepracor Inc, Marlborough | Denver, Colo, Stockton and Encinitas, Calif, Wilmington, NC, and Marlboroug

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.